Trial-Results center  
Clinical trial results database in cardiology Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

DVT prophylaxis - anticoagulant - orthopedic surgery

DVT prophylaxis - antithrombotics - orthopedic surgery


Related trials

Gardecki, 3000 - Ticlopidine vs placebo

Lyon-II, 3000 - Ticlopidine vs placebo

ADVANCE 2, 2010 - apixaban vs enoxaparin (europe regimen)

ADVANCE 3, 2010 - apixaban vs enoxaparin

RECORD 4, 2009 - rivaroxaban vs enoxaparin (US regimen)

DRIVE, 2008 - SR123781A vs enoxaparin

RECORD 3, 2008 - rivaroxaban vs enoxaparin (europe regimen)

RE-MOBILIZE (150mg), 2008 - dabigatran 150mg vs enoxaparin (US regimen)

RECORD 2, 2008 - rivaroxaban (long duration) vs enoxaparin (short duration)

RE-MOBILIZE (220mg), 2008 - dabigatran 220mg vs enoxaparin (US regimen)

RECORD 1, 2008 - rivaroxaban vs enoxaparin

ADVANCE-1, 2008 - apixaban vs enoxaparin (US regimen)

RE-NOVATE (220mg), 2007 - dabigatran 220mg vs enoxaparin

Cohen (L8405), 2007 - compression stocking group vs control (on top fondaparinux)

RE-MODEL (220mg), 2007 - dabigatran 220mg vs enoxaparin (europe regimen)

RE-NOVATE (150mg), 2007 - dabigatran 150mg vs enoxaparin

APROPOS 2.5mg, 2007 - apixaban vs enoxaparin (US regimen)

RE-MODEL (150mg), 2007 - dabigatran 150mg vs enoxaparin (europe regimen)

ODIXa-HIP 10mg, 2006 - rivaroxaban vs enoxaparin (short duration)

ODIXa-KNEE, 2005 - rivaroxaban vs enoxaparin (US regimen)

EXPRESS, 2003 - ximelagatran vs Enoxaparin

Platinum (Colwell), 2003 - ximelagatran vs Enoxaparin

PENTHIFRA�PLUS (Eriksson), 2003 - extended prophylaxis vs standard prophylaxis

PENTATHLON (Turpie), 2002 - fondaparinux vs enoxaparin

METHRO III, 2002 - ximelagatran vs Enoxaparin



See also:

  • All DVT prophylaxis clinical trials
  • All clinical trials of antithrombotics
  • All clinical trials of Acenocoumarol
    		•  

    Samama study, 2001

    download pdf: Acenocoumarol | antithrombotics for DVT prophylaxis

    Treatments

    Studied treatment Acenocoumarol
    Control treatment Reviparin 4200 anti-Xa IU x1

    Patients

    Patients THR

    Method and design

    Randomized effectives 645 / 644 (studied vs. control)
    Blinding Open
    Follow-up duration 6 weeks


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Deep vein thrombosis

    20 / 636
         15 / 643
         classic 1,35 [0,70;2,61]

    Symptomatic pulmonary embolism

    4 / 645
         0 / 644
         classic 16,97 [0,30;957,03]

    Major bleeding

    proximal DVT

    4 / 636
         3 / 643
         classic 1,35 [0,30;6,00]

    All cause death

    2 / 645
         0 / 644
         classic 8,99 [0,14;559,07]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Deep vein thrombosis 20 / 636 (3,1%) 15 / 643 (2,3%) 1,35 [0,70;2,61]
    Symptomatic pulmonary embolism 4 / 645 (0,6%) 0 / 644 (0,1%) 7,99 [0,42;150,79]
    proximal DVT 4 / 636 (0,6%) 3 / 643 (0,5%) 1,35 [0,30;6,00]
    All cause death 2 / 645 (0,3%) 0 / 644 (0,1%) 3,99 [0,18;88,40]
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Deep vein thrombosis 3,14% 2,33% 8,1‰
    proximal DVT 6,29‰ 4,67‰ 1,6‰

    Meta-analysis of all similar trials:

    anticoagulant in DVT prophylaxis for orthopedic surgery

    antithrombotics in DVT prophylaxis for orthopedic surgery



    Reference(s)

    Trials register # NA
    • Samama CM, Vray M, Barr� J, Fiessinger JN, Rosencher N, Lecompte T, Potron G, Basile J, Hull R, Desmichels D. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant.. Arch Intern Med 2002;162:2191-6
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend